Table of Content

1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study


2 RESEARCH METHODOLOGY


3 EXECUTIVE SUMMARY


4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Burden of Cancer and Cardiac Disorders
4.2.2 Increased Technological Advancements
4.2.3 Growth in Applications of Nuclear Medicine and Imaging
4.3 Market Restraints
4.3.1 High Cost of the Techniques
4.3.2 Short Half-life of Radiopharmaceuticals
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry


5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Equipment
5.1.2 By Radioisotope
5.1.2.1 By Diagnostic Technology
5.1.2.1.1 SPECT Radioisotopes
5.1.2.1.1.1 Technetium-99m (TC-99m)
5.1.2.1.1.2 Thallium-201 (TI-201)
5.1.2.1.1.3 Gallium (Ga-67)
5.1.2.1.1.4 Iodine (I-123)
5.1.2.1.1.5 Other SPECT Radioisotopes
5.1.2.1.2 PET Radioisotopes
5.1.2.1.2.1 Fluorine-18 (F-18)
5.1.2.1.2.2 Rubidium-82 (RB-82)
5.1.2.1.2.3 Other PET Radioisotopes
5.2 By Application
5.2.1 SPECT Applications
5.2.1.1 Neurology
5.2.1.2 Cardiology
5.2.1.3 Thyroid
5.2.1.4 Other SPECT Applications
5.2.2 PET Applications
5.2.2.1 Oncology
5.2.2.2 Cardiology
5.2.2.3 Neurology
5.2.2.4 Other PET Applications


6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bayer AG
6.1.2 Bracco Imaging SpA
6.1.3 Canon Inc.
6.1.4 Cardinal Health Inc.
6.1.5 China Isotope & Radiation Corporation (CIRC)
6.1.6 Curium Pharma
6.1.7 GE Healthcare
6.1.8 Global Medical Solutions Ltd
6.1.9 Koninklijke Philips NV
6.1.10 Siemens Healthineers
6.1.11 Yantai Dongcheng Pharmaceutical Group Co. Ltd


7 MARKET OPPORTUNITIES AND FUTURE TRENDS